Free Trial
The Market Does Not Wait. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion
LON:PXS

Provexis 12/31/2025 Earnings Report

GBX 1.03 +0.08 (+8.11%)
As of 12:38 PM Eastern
ProfileEarnings History

Provexis EPS Results

Actual EPS
-GBX 0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Provexis Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Provexis Announcement Details

Quarter
Date
12/31/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Provexis Earnings Headlines

Provexis Secures Shareholder Support and Advances in Chinese Market
November 21, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/provexis-secures-shareholder-support-and-advances-in-chinese-market?utm_source=marketbeat.com&utm_medium=referral
AIM Market Roundup: Provexis, Geo Exploration, Sabien
November 19, 2025  |  sg.finance.yahoo.comhttps://sg.finance.yahoo.com/news/aim-market-roundup-provexis-geo-142747730.html
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel
May 20 at 1:00 AM  |  Porter & Company (Ad)
Provexis Faces Temporary Trading Suspension Amid Financial Reporting Delay
September 30, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/provexis-faces-temporary-trading-suspension-amid-financial-reporting-delay?utm_source=marketbeat.com&utm_medium=referral
Phase I trial finds topical PXS-6302 generally well tolerated in established skin scars
September 12, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/phase-i-trial-finds-topical-pxs-6302-generally-well-tolerated-in-established-skin-scars/ar-AA1MqHQg
Provexis (LON:PXS) Is In A Strong Position To Grow Its Business
June 28, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/provexis-lon-pxs-strong-position-084250241.html
See More Provexis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Provexis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Provexis and other key companies, straight to your email.

About Provexis

Provexis (LON:PXS), together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company's syrup and powder versions of Fruitflow are used in various foods, beverages, and dietary supplement formats. It offers Fruitflow + Omega-3, a supplement in capsule form that supports healthy blood flow and heart function. The company sells its products through distributors and online channels. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.

View Provexis Profile
Earnings Tools